Pfizer's (PFE) animal health spin-off, Zoetis (ZTS) prices its IPO at $26 per share, above the...

Pfizer's (PFE) animal health spin-off, Zoetis (ZTS) prices its IPO at $26 per share, above the expected $22 - $25 range. Shares are expected to begin trading on the NYSE on Friday.

From other sites
Comments (12)
    , contributor
    Comments (2) | Send Message
    I am a retired CPA, now an investor. I guess it's the CPA in me that asks: How can a company trading at 27+ spin off a company that sells at 22-25 without losing value? And since I own Pfizer, how do I benefit? Similar thing happened with COP spinning off Philips 66. How does this work? Educate me.
    31 Jan 2013, 08:45 PM Reply Like
  • MexCom
    , contributor
    Comments (3069) | Send Message
    The market is valuing the spin-off higher than expected. It probably is higher than the asset value being carried on the books. If they were to revalue the balance sheet with market prices, they would realize an extra ordinary gain. PFE is turning out to be an excellent investment. I recently added and now have a full position with an average purchase date of November 2012. It is producing for me a 36% annualized rate of return.
    1 Feb 2013, 05:50 AM Reply Like
  • normanbk
    , contributor
    Comments (42) | Send Message
    At the time I posted my comment, I did not know PFE had an 80% stake that it smart to create value for the PFE stock while retaining control.....
    4 Feb 2013, 06:42 AM Reply Like
  • normanbk
    , contributor
    Comments (42) | Send Message
    When you find out, please let me know.
    31 Jan 2013, 09:54 PM Reply Like
  • StLoMoDan
    , contributor
    Comments (109) | Send Message
    i do not know the details of this spin-off and I am a shareholder in PFE. I can answer you other question. if you owned COP at the time of the PSX spin-off then you should have received 1 share of PSX for every 2 shares of COP. PSX was offered at about $34 per share so COP dropped by $17 per share that day.
    31 Jan 2013, 10:11 PM Reply Like
    , contributor
    Comments (54) | Send Message
    I don't feel so bad after reading DIPENTIMA9's comments with him being a CPA. I am a current Pfizer shareholder and I guess I can't see what the benefit is. Am really perplexed. Some articles I read say it is not a spin off but an IPO. Whatever it is if current shareholders receive nothing in exchange that what is so beneficial about it?? Am not real "up" on this kind of stuff so excuse my ignorance please.
    31 Jan 2013, 10:30 PM Reply Like
  • artheen
    , contributor
    Comments (3) | Send Message
    Some Numbers: Just to put things in perspective.
    Pfizer holds 413.9M shares (after the IPO) of Zoetis. PFE has 7.36B. That works out to 0.056236 ZTS shares for every share of PFE. So if Pfizer decides to distribute ZTS shares to its shareholders 100 PFE shares will get 5.6236 ZTS shares. I think the, impact on PFE shares should be that extent. (0.056236 * 26 = $1.46 , $26 is IPO price, so in theory PFE could go down by that amount, if they decide to distribute their holding at a future date that, $26 will change)
    1 Feb 2013, 09:19 AM Reply Like
  • schil2am
    , contributor
    Comments (2) | Send Message
    I wouldn't focus on the share price so much as I would the market cap of the spinoff. PFE from my understanding will still have a controlling share in the company. With the proceeds of around $4 billion they plan on doing a share repurchase. I believe that they will eventually sell the remainder of their shares in ZTS and hopefully at that time it will be a share swap.
    5 Feb 2013, 09:20 AM Reply Like
  • angelamaas
    , contributor
    Comments (11) | Send Message
    I think ZTS can be $26/share when PFE is around $27 because there are more outstanding shares in PFE.


    So if there are only 1 millions shares of ZTS for example (I have no clue how many shares are being sold) it is only valued at $26 million versus around a billion shares of pfizer at $27 each and a 200Billion value.


    Pfizer is selling a 20% stake of Zoetis and keeping 80% ownership.


    As far as I could tell, it looks like Pfizer shareholders get nothing from this deal, except that Pfizer is collecting some upfront cash for the IPO (minus the charges to Goldman Sachs and the other banks frontrunning the deal of course.)


    I sold all of my shares in Pfizer on January 30th after 12 long years... Maybe it was a bad decision? Time will tell...
    5 Feb 2013, 12:43 PM Reply Like
  • BPfix
    , contributor
    Comments (17) | Send Message
    I think I will wait for it to drop.
    5 Feb 2013, 02:40 PM Reply Like
  • User 558853
    , contributor
    Comment (1) | Send Message
    Good question. I'm an accountant and PFE shareholder too. How does this spinoff benefit the shareholder?
    5 Feb 2013, 02:44 PM Reply Like
    , contributor
    Comments (54) | Send Message
    This is for you CPA's out there. Wouldn't the spin off affect the cost basis of the parent company Pfizer? For people who now sell their PFE shares after the spin off wouldn't the basis have to be adjusted?
    6 Feb 2013, 07:56 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs